Gain Therapeutics, Inc.
GANX Healthcare Biotechnology
Gain Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $55,200.00, down 60.6% from fiscal 2022. In the quarter to June 2026, EPS grew 42.1%, free cash flow grew 8.22% and total debt fell 23.9%, each against the same quarter a year earlier.
Follow GANX
Gain Therapeutics, Inc. (GANX) EV/Sales
As of 16 October 2026, Gain Therapeutics, Inc. (GANX) trades at a EV/Sales of 211×. Over the past ten years it has ranged from −82.0× (June 2021) to 1,129× (April 2021); the current reading is higher than 54% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 159× | 53.43% |
| FY2022 | 103× | (10.19%) |
| FY2021 | 115× | (85.69%) |
| FY2020 | 805× | 0.00% |
| FY2019 | 805× | 0.00% |
| FY2018 | 805× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2023 | 206× | 99.43% |
| Dec 2022 | 103× | 13.73% |
| Jun 2022 | 91.0× | 24.90% |
| Mar 2022 | 72.8× | (36.78%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TENX Tenax Therapeutics, Inc. compare | −142× |
| PLRX Pliant Therapeutics, Inc. compare | −14.3× |
| BMEA Biomea Fusion, Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | 0.6× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 8.6× |
| GANX Gain Therapeutics, Inc. | 211× |
| GUTS Fractyl Health, Inc. compare | 2,465× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)